Trop-2 expression in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in non-small cell lung cancer (NSCLC), making it a promising target for antibody-drug conjugates (ADCs).
• Understanding Trop-2 expression at the protein level is crucial for evaluating Trop-2 ADC efficacy, but current knowledge is limited.

Purpose of the Study:

• To comprehensively characterize Trop-2 expression at both mRNA and protein levels across diverse NSCLC datasets.
• To investigate the relationship between Trop-2 expression and clinical-pathological features, genetic alterations, and patient prognosis in NSCLC.

Main Methods:

• Analysis of Trop-2 mRNA, mutation, and protein expression using The Cancer Genome Atlas (TCGA) and two independent sample sets.
• Utilized immunohistochemistry (SP295 clone) and RNA sequencing for protein and RNA expression profiling.
• Correlated Trop-2 expression with clinical data, including histology, baseline characteristics, and survival outcomes.

Main Results:

• Trop-2 was highly expressed in NSCLC, with similar expression patterns observed in adenocarcinoma and squamous cell carcinoma.
• Trop-2 expression was independent of patient age, sex, tumor stage, and clinically relevant genetic alterations.
• Protein-level Trop-2 expression was detected in 82% to 90% of NSCLC cases across the analyzed sample sets.

Conclusions:

• High Trop-2 expression is a common feature across NSCLC subtypes and is not associated with prognostic factors or specific driver mutations.
• The widespread and consistent Trop-2 protein expression in NSCLC supports its broad applicability as a target for antibody-drug conjugates.